Clinical commissioning policy statement: Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)

Document first published:
Page updated:
Topic:
Publication type:

Adalimumab is not recommended to be available as a treatment option through routine commissioning for refractory chronic non-bacterial osteomyelitis/osteitis (all ages).